Unlike fecal transplants, which require use of donors and are an untargeted, inherently variable procedure, bacterial consortia therapeutics are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. We isolate beneficial gut bacteria and grow them in-house in a controlled, consistent, and scalable way. And unlike reductionistic approaches such as single strain probiotics, bacterial consortia can robustly shift the gut ecosystem.
Vedanta's bacterial consortia therapeutics are easily administered as lyophilized powder in oral capsule form. We manufacture these bacteria in our state-of-the-art CGMP facilities and process them into convenient oral capsule formulations for administration to patients.
The active ingredients travel down the gastrointestinal tract and colonize the intestine. Unlike probiotics, our drugs are based on the dominant, most abundant dwellers of the human intestine. They can shift the composition of the gut microbiota and provide colonization resistance against a range of intestinal infectious pathogens.
Our drugs can stimulate a range of immune responses ranging from immunoregulatory responses, which hold potential in the treatment of autoimmune and allergic diseases, to immunopotentiating responses, which hold potential in cancer and vaccination.
Our platform enables identification of defined bacterial consortia with drug-like properties and their manufacture to GMP standards.
How Our Proprietary Discovery and Development Platform Works
